Medical facility organization, Field Medical, raises $35 million to advance its FieldForce platform technology.
**Field Medical Raises $35 Million for Pulsed Field Ablation Technology, Expanding into Ventricular Tachycardia**
Field Medical, Inc., a pioneering company in the field of Pulsed Field Ablation (PFA) technology, has announced the successful closure of a $35 million Series B financing round. This brings the total funding raised by the company to $75 million.
The funding round was co-led by BioStar Capital and Cue Growth, with institutional governance expertise provided by Ben Cannon, Founding Partner of Cue Growth, who has been appointed to Field Medical's Board of Directors.
The funds will support the initiation of the company's pivotal VERITAS trial, aimed at evaluating the safety and efficacy of Field Medical's PFA technology in treating ventricular tachycardia (VT), a complex and often life-threatening arrhythmia.
The financing round will also further expand Field Medical's clinical and regulatory capabilities, and advance the development of the FieldForce Ablation System.
The decision to focus on VT comes as PFA technology has made significant strides in treating atrial fibrillation (AF), with promising expansion into more complex arrhythmias. While most commercial and clinical focus currently centers on AF, notable progress is being made in applying PFA to VT.
Boston Scientific has expressed intent to extend clinical trials to more complex arrhythmias, including redo ablations and arrhythmias beyond AF, which logically includes VT given its clinical relevance. Field Medical, Inc. is among companies actively involved in this advancement, developing PFA systems that harness non-thermal energy delivery to selectively ablate arrhythmogenic tissue in the ventricles with minimal collateral injury.
PFA offers several key advantages in complex arrhythmia ablation, including selective tissue ablation, improved safety, efficiency, and compatibility with advanced mapping systems. These features make PFA particularly valuable in ventricular ablations where collateral damage risk is high.
The ADVANTAGE II clinical trial demonstrated high efficacy (around 73%) in persistent AF, with benefits over thermal ablation including faster procedures, high tissue specificity, and reduced collateral damage. Boston Scientific expanded FARAPULSE’s FDA approval in mid-2025 to treat drug-refractory, symptomatic persistent AF, reflecting growing confidence in PFA’s safety and effectiveness.
Johnson & Johnson launched their VARIPULSE™ PFA platform integrated with CARTO™ 3 mapping to enhance procedural accuracy and reproducibility, indicating technological maturation and better integration with electrophysiology tools.
Louis Cannon, MD, the founder and senior managing director of BioStar Capital, expressed support for Field Medical's transformative technology tackling under-addressed challenges in cardiology. The company's Board of Directors has been expanded with the addition of Mark Wisniewski, Marlu Janssen, and Ben Cannon.
Marlu Janssen brings a background in commercial, product, and clinical strategy leadership in cardiology and emerging medtech. Alexei Mlodinow, with a track record in medtech innovation and multiple exits, has also been appointed to Field Medical's Board of Directors.
Steven Mickelsen, MD, the founder and CEO of Field Medical, stated that their next-generation therapy is poised to unlock opportunities in ventricular tachycardia care for high-risk patients. The company's latest appointment, Mark Wisniewski as the Chairperson of Field Medical's Board of Directors, will provide strategic guidance and leadership to drive this mission forward.
The future of PFA in ventricular tachycardia care looks promising, with further clinical trial data anticipated to solidify the role of PFA in ventricular arrhythmias. As Field Medical, Inc. continues to make strides in this field, the potential to revolutionize cardiology and improve patient outcomes is within reach.
- Science has played a crucial role in the advancement of Pulsed Field Ablation (PFA) technology, particularly in its application towards complex medical-conditions like ventricular tachycardia (VT).
- In the realm of health-and-wellness, Field Medical's PFA technology shows promise for the treatment of VT, a serious arrhythmia, with the company raising $35 million through a Series B financing round to further their research and development in this area.
- The business potential of PFA technology extends beyond finance, with technology companies like Boston Scientific and Johnson & Johnson investing in the integration of PFA systems with advanced mapping tools, aiming to enhance their efficiency and safety in treating cardiovascular-health issues such as ventricular arrhythmias.